COVID-19-Related Antibodies
Recombinant mAbs for SARS-CoV-2 Research
Monoclonal antibodies (mAbs) against SARS-CoV-2 antigens or host pro-inflammatory cytokine receptors are under therapeutic investigation for fighting COVID-19. InvivoGen offers isotype families of recombinant mAbs related to COVID-19 research.
- Anti-SARS-CoV Spike isotype family (clone CR3022) - targets the SARS-CoV spike RBD
- Anti-SARS-CoV-2 Spike mAb (clone H4) - targets the SARS-CoV-2 spike RBD
- Anti-SARS-CoV-2 Spike mAb (clone B38) - targets the SARS-CoV-2 spike RBD
- Anti-SARS-CoV Nucleocapsid mAb (clone CR3018) - targets the SARS-CoV nucleocapsid
- Anti-hIL-6R isotype family (Tocilizumab-derived) - targets the human interleukin 6 receptor
ISOTYPE FAMILIES
These antibodies are available with different immunoglobulin isotypes, either native or engineered. The different isotypes can trigger or hinder mAb effector functions including, complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). Depending on your target and application, InvivoGen offers:
- Human isotypes
hIgG1: highly-represented in the serum and a potent inducer of ADCC and CDC
hIgG1NQ: non-glycosylated hIgG1 exhibiting ablated ADCC and severely compromised CDC
hIgA: main antibody isotype present in mucosal secretions (i.e. in the respiratory tract) and a moderate inducer of ADCC
hIgM: first antibody isotype raised in the immune response and a potent inducer of CDC
- Mouse isotypes
mIgG2a: most potent inducer of ADCC and CDC among murine isotypes
mIgG1e3: effectorless mIgG1 with a D265A point mutation
As a guarantee of quality, our antibody constructs are fully sequenced and their target binding has been validated.
InvivoGen’s products are for research use only, and not for clinical or veterinary use.
Read our reviews on COVID-19
➤ The infection cycle of SARS-CoV-2
➤ Treatment with repurposed drugs
➤ Predicted host immune responses to SARS-CoV-2
➤ Vaccine development
➤ Protective immunity & Re-infection